Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients
Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of...
Gespeichert in:
| Veröffentlicht in: | PloS one 2013-03, Vol.8 (3), p.e59941-e59941 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e59941 |
|---|---|
| container_issue | 3 |
| container_start_page | e59941 |
| container_title | PloS one |
| container_volume | 8 |
| creator | Nunes, Fabio P Merker, Vanessa L Jennings, Dominique Caruso, Paul A di Tomaso, Emmanuelle Muzikansky, Alona Barker, 2nd, Fred G Stemmer-Rachamimov, Anat Plotkin, Scott R |
| description | Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of meningiomas in NF2 patients who received bevacizumab for treatment of progressive vestibular schwannomas. A radiographic response was defined as a 20% decrease in tumor size by volumetric MRI analysis. In addition, we determined the expression pattern of growth factors associated with tumor angiogenesis in paraffin-embedded tissues from 26 unrelated meningiomas. A total of 48 meningiomas in 15 NF2 patients were included in this study with a median follow up time of 18 months. A volumetric radiographic response was seen in 29% of the meningiomas (14/48). Tumor shrinkage was not durable: the median duration of response was 3.7 months and the median time to progression was 15 months. There was no significant correlation between pre-treatment growth rate and meningioma response in regression models. Tissue analysis showed no correlation between tumor microvascular density and expression of VEGF pathway components. This data suggests that, in contrast to schwannomas, activation of VEGF pathway is not the primary driver of angiogenesis in meningiomas. Our results suggest that a minority of NF2-associated meningiomas shrink during bevacizumab therapy and that these responses were of short duration. These results are comparable to previous studies of bevacizumab in sporadic meningiomas. |
| doi_str_mv | 10.1371/journal.pone.0059941 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1330891492</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478173008</galeid><doaj_id>oai_doaj_org_article_f1f7da0af9c04824ac2ec64c9d11a7a4</doaj_id><sourcerecordid>A478173008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-7df4ae805b7d5a9631150c249a1adad4cb146aba41f7d31bf9a736c16768f8f03</originalsourceid><addsrcrecordid>eNqNklGL1DAUhYso7rr6D0QLgujDjEmTpo0Pwrq4OrC4oK6v4TZNZjK0TTdJB9dfb-p0l6nsg-ShIf3Oubk3J0meY7TEpMDvtnZwHTTL3nZqiVDOOcUPkmPMSbZgGSIPD_ZHyRPvtxEiJWOPk6OM5HleUnScXH1UO5Dm99BClQanILSqC6m2Lo0b062NbcGnpku_nmfvU0idCs76XslgdiqFeIMbb3xqdYrztIdgotw_TR5paLx6Nn1PkqvzTz_OviwuLj-vzk4vFpLxLCyKWlNQJcqros6BM4JxjmRGOWCooaaywpRBBRTroia40hwKwiRmBSt1qRE5SV7uffvGejFNxAtMCCo5pjyLxGpP1Ba2onemBXcjLBjx98C6tQAXjGyU0GMVQKC5RLTMKMhMSUYlrzGGAmj0-jBVG6pW1TJ26qCZmc7_dGYj1nYnCIuTp6PBm8nA2etB-SBa46VqGuiUHcZ7Z5SUBWdjZ6_-Qe_vbqLWEBswnbaxrhxNxSktSlwQhMpILe-h4qpVa2SMjzbxfCZ4OxNEJqhfYQ2D92L1_dv_s5c_5-zrA3ajoAkbb5shGNv5OUj3oIxZ807puyFjJMb0305DjOkXU_qj7MXhA92JbuNO_gBk6P8K</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1330891492</pqid></control><display><type>article</type><title>Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>PMC (PubMed Central)</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Nunes, Fabio P ; Merker, Vanessa L ; Jennings, Dominique ; Caruso, Paul A ; di Tomaso, Emmanuelle ; Muzikansky, Alona ; Barker, 2nd, Fred G ; Stemmer-Rachamimov, Anat ; Plotkin, Scott R</creator><contributor>O. Pieper, Russell</contributor><creatorcontrib>Nunes, Fabio P ; Merker, Vanessa L ; Jennings, Dominique ; Caruso, Paul A ; di Tomaso, Emmanuelle ; Muzikansky, Alona ; Barker, 2nd, Fred G ; Stemmer-Rachamimov, Anat ; Plotkin, Scott R ; O. Pieper, Russell</creatorcontrib><description>Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of meningiomas in NF2 patients who received bevacizumab for treatment of progressive vestibular schwannomas. A radiographic response was defined as a 20% decrease in tumor size by volumetric MRI analysis. In addition, we determined the expression pattern of growth factors associated with tumor angiogenesis in paraffin-embedded tissues from 26 unrelated meningiomas. A total of 48 meningiomas in 15 NF2 patients were included in this study with a median follow up time of 18 months. A volumetric radiographic response was seen in 29% of the meningiomas (14/48). Tumor shrinkage was not durable: the median duration of response was 3.7 months and the median time to progression was 15 months. There was no significant correlation between pre-treatment growth rate and meningioma response in regression models. Tissue analysis showed no correlation between tumor microvascular density and expression of VEGF pathway components. This data suggests that, in contrast to schwannomas, activation of VEGF pathway is not the primary driver of angiogenesis in meningiomas. Our results suggest that a minority of NF2-associated meningiomas shrink during bevacizumab therapy and that these responses were of short duration. These results are comparable to previous studies of bevacizumab in sporadic meningiomas.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0059941</identifier><identifier>PMID: 23555840</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Adult ; Angiogenesis ; Angiogenesis inhibitors ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Atrophy ; Bevacizumab ; Brain cancer ; Brain Neoplasms - drug therapy ; Brain research ; Cancer therapies ; Care and treatment ; Correlation ; Correlation analysis ; Female ; Genetic disorders ; Growth factors ; Growth rate ; Hospitals ; Humans ; Image Processing, Computer-Assisted ; Immunohistochemistry ; Immunotherapy ; Magnetic Resonance Imaging ; Male ; Medicine ; Meningioma ; Meningioma - drug therapy ; Meningioma - etiology ; Metastasis ; Microvasculature ; Middle Aged ; Monoclonal antibodies ; Neovascularization, Pathologic - drug therapy ; Neurofibromatosis ; Neurofibromatosis 2 ; Neurofibromatosis 2 - complications ; Neurofibromin 2 ; Neurological disorders ; Neurology ; Neuroma, Acoustic - drug therapy ; Paraffin ; Patients ; Pretreatment ; Radiation therapy ; Regression Analysis ; Regression models ; Retrospective Studies ; Shrinkage ; Software ; Targeted cancer therapy ; Time Factors ; Tissue analysis ; Tissues ; Treatment Outcome ; Tumors ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - metabolism ; Vestibular system ; Young Adult</subject><ispartof>PloS one, 2013-03, Vol.8 (3), p.e59941-e59941</ispartof><rights>COPYRIGHT 2013 Public Library of Science</rights><rights>2013 Nunes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013 Nunes et al 2013 Nunes et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-7df4ae805b7d5a9631150c249a1adad4cb146aba41f7d31bf9a736c16768f8f03</citedby><cites>FETCH-LOGICAL-c692t-7df4ae805b7d5a9631150c249a1adad4cb146aba41f7d31bf9a736c16768f8f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605344/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605344/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23555840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>O. Pieper, Russell</contributor><creatorcontrib>Nunes, Fabio P</creatorcontrib><creatorcontrib>Merker, Vanessa L</creatorcontrib><creatorcontrib>Jennings, Dominique</creatorcontrib><creatorcontrib>Caruso, Paul A</creatorcontrib><creatorcontrib>di Tomaso, Emmanuelle</creatorcontrib><creatorcontrib>Muzikansky, Alona</creatorcontrib><creatorcontrib>Barker, 2nd, Fred G</creatorcontrib><creatorcontrib>Stemmer-Rachamimov, Anat</creatorcontrib><creatorcontrib>Plotkin, Scott R</creatorcontrib><title>Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of meningiomas in NF2 patients who received bevacizumab for treatment of progressive vestibular schwannomas. A radiographic response was defined as a 20% decrease in tumor size by volumetric MRI analysis. In addition, we determined the expression pattern of growth factors associated with tumor angiogenesis in paraffin-embedded tissues from 26 unrelated meningiomas. A total of 48 meningiomas in 15 NF2 patients were included in this study with a median follow up time of 18 months. A volumetric radiographic response was seen in 29% of the meningiomas (14/48). Tumor shrinkage was not durable: the median duration of response was 3.7 months and the median time to progression was 15 months. There was no significant correlation between pre-treatment growth rate and meningioma response in regression models. Tissue analysis showed no correlation between tumor microvascular density and expression of VEGF pathway components. This data suggests that, in contrast to schwannomas, activation of VEGF pathway is not the primary driver of angiogenesis in meningiomas. Our results suggest that a minority of NF2-associated meningiomas shrink during bevacizumab therapy and that these responses were of short duration. These results are comparable to previous studies of bevacizumab in sporadic meningiomas.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Angiogenesis</subject><subject>Angiogenesis inhibitors</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Atrophy</subject><subject>Bevacizumab</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain research</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Correlation</subject><subject>Correlation analysis</subject><subject>Female</subject><subject>Genetic disorders</subject><subject>Growth factors</subject><subject>Growth rate</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Image Processing, Computer-Assisted</subject><subject>Immunohistochemistry</subject><subject>Immunotherapy</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Meningioma</subject><subject>Meningioma - drug therapy</subject><subject>Meningioma - etiology</subject><subject>Metastasis</subject><subject>Microvasculature</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neurofibromatosis</subject><subject>Neurofibromatosis 2</subject><subject>Neurofibromatosis 2 - complications</subject><subject>Neurofibromin 2</subject><subject>Neurological disorders</subject><subject>Neurology</subject><subject>Neuroma, Acoustic - drug therapy</subject><subject>Paraffin</subject><subject>Patients</subject><subject>Pretreatment</subject><subject>Radiation therapy</subject><subject>Regression Analysis</subject><subject>Regression models</subject><subject>Retrospective Studies</subject><subject>Shrinkage</subject><subject>Software</subject><subject>Targeted cancer therapy</subject><subject>Time Factors</subject><subject>Tissue analysis</subject><subject>Tissues</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Vestibular system</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNklGL1DAUhYso7rr6D0QLgujDjEmTpo0Pwrq4OrC4oK6v4TZNZjK0TTdJB9dfb-p0l6nsg-ShIf3Oubk3J0meY7TEpMDvtnZwHTTL3nZqiVDOOcUPkmPMSbZgGSIPD_ZHyRPvtxEiJWOPk6OM5HleUnScXH1UO5Dm99BClQanILSqC6m2Lo0b062NbcGnpku_nmfvU0idCs76XslgdiqFeIMbb3xqdYrztIdgotw_TR5paLx6Nn1PkqvzTz_OviwuLj-vzk4vFpLxLCyKWlNQJcqros6BM4JxjmRGOWCooaaywpRBBRTroia40hwKwiRmBSt1qRE5SV7uffvGejFNxAtMCCo5pjyLxGpP1Ba2onemBXcjLBjx98C6tQAXjGyU0GMVQKC5RLTMKMhMSUYlrzGGAmj0-jBVG6pW1TJ26qCZmc7_dGYj1nYnCIuTp6PBm8nA2etB-SBa46VqGuiUHcZ7Z5SUBWdjZ6_-Qe_vbqLWEBswnbaxrhxNxSktSlwQhMpILe-h4qpVa2SMjzbxfCZ4OxNEJqhfYQ2D92L1_dv_s5c_5-zrA3ajoAkbb5shGNv5OUj3oIxZ807puyFjJMb0305DjOkXU_qj7MXhA92JbuNO_gBk6P8K</recordid><startdate>20130321</startdate><enddate>20130321</enddate><creator>Nunes, Fabio P</creator><creator>Merker, Vanessa L</creator><creator>Jennings, Dominique</creator><creator>Caruso, Paul A</creator><creator>di Tomaso, Emmanuelle</creator><creator>Muzikansky, Alona</creator><creator>Barker, 2nd, Fred G</creator><creator>Stemmer-Rachamimov, Anat</creator><creator>Plotkin, Scott R</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130321</creationdate><title>Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients</title><author>Nunes, Fabio P ; Merker, Vanessa L ; Jennings, Dominique ; Caruso, Paul A ; di Tomaso, Emmanuelle ; Muzikansky, Alona ; Barker, 2nd, Fred G ; Stemmer-Rachamimov, Anat ; Plotkin, Scott R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-7df4ae805b7d5a9631150c249a1adad4cb146aba41f7d31bf9a736c16768f8f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Angiogenesis</topic><topic>Angiogenesis inhibitors</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Atrophy</topic><topic>Bevacizumab</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain research</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Correlation</topic><topic>Correlation analysis</topic><topic>Female</topic><topic>Genetic disorders</topic><topic>Growth factors</topic><topic>Growth rate</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Image Processing, Computer-Assisted</topic><topic>Immunohistochemistry</topic><topic>Immunotherapy</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Meningioma</topic><topic>Meningioma - drug therapy</topic><topic>Meningioma - etiology</topic><topic>Metastasis</topic><topic>Microvasculature</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neurofibromatosis</topic><topic>Neurofibromatosis 2</topic><topic>Neurofibromatosis 2 - complications</topic><topic>Neurofibromin 2</topic><topic>Neurological disorders</topic><topic>Neurology</topic><topic>Neuroma, Acoustic - drug therapy</topic><topic>Paraffin</topic><topic>Patients</topic><topic>Pretreatment</topic><topic>Radiation therapy</topic><topic>Regression Analysis</topic><topic>Regression models</topic><topic>Retrospective Studies</topic><topic>Shrinkage</topic><topic>Software</topic><topic>Targeted cancer therapy</topic><topic>Time Factors</topic><topic>Tissue analysis</topic><topic>Tissues</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Vestibular system</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nunes, Fabio P</creatorcontrib><creatorcontrib>Merker, Vanessa L</creatorcontrib><creatorcontrib>Jennings, Dominique</creatorcontrib><creatorcontrib>Caruso, Paul A</creatorcontrib><creatorcontrib>di Tomaso, Emmanuelle</creatorcontrib><creatorcontrib>Muzikansky, Alona</creatorcontrib><creatorcontrib>Barker, 2nd, Fred G</creatorcontrib><creatorcontrib>Stemmer-Rachamimov, Anat</creatorcontrib><creatorcontrib>Plotkin, Scott R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints in Context (Gale)</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nunes, Fabio P</au><au>Merker, Vanessa L</au><au>Jennings, Dominique</au><au>Caruso, Paul A</au><au>di Tomaso, Emmanuelle</au><au>Muzikansky, Alona</au><au>Barker, 2nd, Fred G</au><au>Stemmer-Rachamimov, Anat</au><au>Plotkin, Scott R</au><au>O. Pieper, Russell</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2013-03-21</date><risdate>2013</risdate><volume>8</volume><issue>3</issue><spage>e59941</spage><epage>e59941</epage><pages>e59941-e59941</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some neurofibromatosis 2 (NF2) patients but its effect on meningiomas has not been defined. To determine the clinical activity of bevacizumab against NF2-related meningiomas, we measured changes in volume of meningiomas in NF2 patients who received bevacizumab for treatment of progressive vestibular schwannomas. A radiographic response was defined as a 20% decrease in tumor size by volumetric MRI analysis. In addition, we determined the expression pattern of growth factors associated with tumor angiogenesis in paraffin-embedded tissues from 26 unrelated meningiomas. A total of 48 meningiomas in 15 NF2 patients were included in this study with a median follow up time of 18 months. A volumetric radiographic response was seen in 29% of the meningiomas (14/48). Tumor shrinkage was not durable: the median duration of response was 3.7 months and the median time to progression was 15 months. There was no significant correlation between pre-treatment growth rate and meningioma response in regression models. Tissue analysis showed no correlation between tumor microvascular density and expression of VEGF pathway components. This data suggests that, in contrast to schwannomas, activation of VEGF pathway is not the primary driver of angiogenesis in meningiomas. Our results suggest that a minority of NF2-associated meningiomas shrink during bevacizumab therapy and that these responses were of short duration. These results are comparable to previous studies of bevacizumab in sporadic meningiomas.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23555840</pmid><doi>10.1371/journal.pone.0059941</doi><tpages>e59941</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2013-03, Vol.8 (3), p.e59941-e59941 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1330891492 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; PMC (PubMed Central); DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Adolescent Adult Angiogenesis Angiogenesis inhibitors Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Atrophy Bevacizumab Brain cancer Brain Neoplasms - drug therapy Brain research Cancer therapies Care and treatment Correlation Correlation analysis Female Genetic disorders Growth factors Growth rate Hospitals Humans Image Processing, Computer-Assisted Immunohistochemistry Immunotherapy Magnetic Resonance Imaging Male Medicine Meningioma Meningioma - drug therapy Meningioma - etiology Metastasis Microvasculature Middle Aged Monoclonal antibodies Neovascularization, Pathologic - drug therapy Neurofibromatosis Neurofibromatosis 2 Neurofibromatosis 2 - complications Neurofibromin 2 Neurological disorders Neurology Neuroma, Acoustic - drug therapy Paraffin Patients Pretreatment Radiation therapy Regression Analysis Regression models Retrospective Studies Shrinkage Software Targeted cancer therapy Time Factors Tissue analysis Tissues Treatment Outcome Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - metabolism Vestibular system Young Adult |
| title | Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A57%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bevacizumab%20treatment%20for%20meningiomas%20in%20NF2:%20a%20retrospective%20analysis%20of%2015%20patients&rft.jtitle=PloS%20one&rft.au=Nunes,%20Fabio%20P&rft.date=2013-03-21&rft.volume=8&rft.issue=3&rft.spage=e59941&rft.epage=e59941&rft.pages=e59941-e59941&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0059941&rft_dat=%3Cgale_plos_%3EA478173008%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1330891492&rft_id=info:pmid/23555840&rft_galeid=A478173008&rft_doaj_id=oai_doaj_org_article_f1f7da0af9c04824ac2ec64c9d11a7a4&rfr_iscdi=true |